References of "Beckers, Albert"
     in
Bookmark and Share    
See detailFactors influencing pharmacological treatment in acromegaly
Beckers, Albert ULg

Scientific conference (2009, March)

Detailed reference viewed: 4 (0 ULg)
See detailAspects cliniques et génétiques d'adénomes hypophysaires familiaux et sporadiques
Beckers, Albert ULg

Scientific conference (2009, January 22)

Detailed reference viewed: 9 (0 ULg)
See detailToute la thyroïdologie courante en 75 minutes
Beckers, Albert ULg

Scientific conference (2009, January 16)

Detailed reference viewed: 12 (3 ULg)
See detailCaractérisation clinique et génétique des adénomes hypophysaires familiaux (FIPA)
Beckers, Albert ULg

Scientific conference (2009, January 15)

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailAdénomes hypophysaires familiaux.
Burlacu, M. C.; Tichomirowa, M.; Daly, Adrian ULg et al

in Presse Médicale (2009), 38(1), 112-116

Familial pituitary adenomas are found in multitumoral syndromes such as multiple endocrine neoplasia type 1 (NEM1) and type 4 (NEM4) and the Carney complex (CNC); it remains at present the only known ... [more ▼]

Familial pituitary adenomas are found in multitumoral syndromes such as multiple endocrine neoplasia type 1 (NEM1) and type 4 (NEM4) and the Carney complex (CNC); it remains at present the only known condition in the category of familial isolated pituitary adenomas (FIPA). Familial adenomas account for 3-5% of all pituitary adenomas. Their pathogenesis is known in part: mutations of the menin gene in NEM1 (80%), of the CDKN1B gene in NEM4 (several cases described), of the PRKR1A gene in CNC (50%) and the AIP gene in 15% of FIPA cases (50% of the FIPA cases with a homogeneous somatotropic phenotype). The clinical course of familial adenoma with NEM1 or FIPA is more aggressive than that of sporadic adenoma, with more macroadenomas and more patients diagnosed younger. Familial pituitary adenomas are distinguished from the sporadic forms in their genetic, epidemiologic and clinical characteristics. They require a differentiated management, especially concerning screening. [less ▲]

Detailed reference viewed: 31 (9 ULg)
See detailLa mutazione R304X del gene AIP negli adenomi ipofisari : caratteristiche bio-cliniche e aspetti genetici e funzionali
Jaffrain-Réa, M. L.; Occhi, G.; de Menis, E. et al

in 4th Incontri Italiano Sulle Malattie Ipotalamo-Ipofisarie : Ferrara 29-31 gennaio 2009 (2009, January)

Detailed reference viewed: 35 (0 ULg)
Full Text
Peer Reviewed
See detailTesticular effects of isolated luteinizing hormone deficiency and reversal by long-term human chorionic gonadotropin treatment.
Valdes Socin, Hernan Gonzalo ULg; Salvi, Roberto; Thiry, Albert ULg et al

in Journal of Clinical Endocrinology and Metabolism (2009), 94(1), 3-4

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailUpdate on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma.
Daly, Adrian ULg; Tichomirowa, M. A.; Beckers, Albert ULg

in Hormone Research (2009), 71(Suppl 1), 105-111

BACKGROUND: Pituitary adenomas occur in a familial setting in about 5% of all cases and over half of these are due to multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Since the late ... [more ▼]

BACKGROUND: Pituitary adenomas occur in a familial setting in about 5% of all cases and over half of these are due to multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Since the late 1990s, we have described non-MEN1/CNC familial pituitary tumors that include all tumor phenotypes and have named this condition 'familial isolated pituitary adenoma' (FIPA). Clinical features of FIPA differ from those of sporadic pituitary adenomas in that patients with FIPA are often younger and have larger tumors at diagnosis. About 15% of FIPA patients have mutations in the aryl hydrocarbon receptor interacting protein gene (AIP), which indicates that FIPA may have a diverse genetic pathophysiology. We review the clinical features of FIPA, the tumor pathologies found in this setting and the genetic/molecular data that have been recently reported. CONCLUSIONS: Clinically relevant pituitary adenomas are more common than previously thought and occur in a familial setting in about 5% of cases overall. Therefore, specific questioning regarding family history of pituitary disease should be part of the workup of all patients with pituitary adenomas, not just those with acromegaly. FIPA is a useful clinical framework to study the features of pituitary adenomas that occur in a familial setting since it encompasses all tumor phenotypes and heterogeneous/homogeneous expression among affected family members. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailLearning from recombinant GH treatment in obesity
Vandeva, S.; Rixhon, M.; Tichomirova, M. A. et al

in Obesity and Metabolism (2009), 5(3/4), 156-166

Obese and untreated growth hormone deficiency (GHD) patients have a number of similar clinical and biological abnormalities. Treatment with recombinant human growth hormone (rhGH) in GHD patients has ... [more ▼]

Obese and untreated growth hormone deficiency (GHD) patients have a number of similar clinical and biological abnormalities. Treatment with recombinant human growth hormone (rhGH) in GHD patients has proven effective in beneficially modulating body composition and certain cardiovascular risk factors, thus leading to the hypothesis that administration of rhGH in obese patients could show similar beneficial results. Hyperinsulinism and increased free fatty acid levels are the main factors causing reduced GH release in the setting of obesity. We reviewed the outcomes of 25 adult and paediatric clinical studies carried out in 1987-2009 that examined the effects of rhGH administration in the obese state. Body composition showed mainly a reduction in visceral abdominal fat, whereas total bodyweight increased or remained unchanged. Effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients were heterogeneous. The increasing burden of obesity on one hand, the absence of definitive medical treatment on the other, give rise to grounds for considering rhGH as a possible therapeutic option if not in the general obese population, at least in patients with higher risk of cardiovascular morbidity and mortality. [less ▲]

Detailed reference viewed: 14 (1 ULg)
See detailAn analysis of the role of cyclin dependant kinase inhibitor 1B (CDKN1B) gene mutations in 86 families with familial isolated pituitary adenomas (FIPA)
Tichomirova, M. A.; Daly, Adrian ULg; Pujol, Julien ULg et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 28 (7 ULg)
See detailTSH-secreting pituitary adenoma in a male patient with a novel missense AIP mutation
Fajardo Montanana, C.; Daly, Adrian ULg; Tichomirova, M. A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 15 (1 ULg)
See detailHigh Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas
Tichomirova, M. A.; Daly, Adrian ULg; Barlier, A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 24 (2 ULg)
See detailA phase II exploratory study of BIM23A760 in acromegalic patients : preliminary results of safety and efficacy after a single-dose administration
Lesage, C.; Seymour, C.; Urbanavicius, V. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 40 (0 ULg)
See detailCushing disease : Influence of microsurgery on hormonal balance
Vroonen, Laurent ULg; Martin, Didier ULg; Valdes Socin, Hernan Gonzalo ULg et al

in European Neuroendocrine Association - Workshop : Novel insights in the management of Cushing's syndrome (2009)

Detailed reference viewed: 19 (2 ULg)
See detailCushing disease : Pituitary microsurgery on hormonal balance
Stevenaert, Achille ULg; Vroonen, Laurent ULg; Perrin, G. et al

in European Neuroendocrine Association - Workshop : Novel insights in the management of Cushing's syndrome (2009)

Detailed reference viewed: 16 (1 ULg)
See detailThe Genetics in Cushing syndrome
Vandeva, S.; Daly, Adrian ULg; Vroonen, Laurent ULg et al

in European Neuroendocrine Association - Workshop : Novel experimental data on the pituitary and adrenal tumors responsible for Cushing's syndrome (2009)

Detailed reference viewed: 6 (0 ULg)
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in 19 Meeting of the Belgian Endocrine and Metabolic societies (2009)

Detailed reference viewed: 15 (2 ULg)
See detailElevated GH and normal IGF-1
Beckers, Albert ULg

in Acromegaly Consensus (2009)

Detailed reference viewed: 3 (0 ULg)
See detailElevated GH and normal IGF-1 : Discrepant biochemical results
Beckers, Albert ULg

Scientific conference (2009)

Detailed reference viewed: 16 (0 ULg)